Small Cell Lung Cancer Clinical Trials in Detroit, Michigan

6 studies are recruiting for small cell lung cancer in Detroit, Michigan right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   Karmanos Cancer Institute, Detroit, Michigan

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

2. A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

   The purpose of this study is to evaluate the efficacy and safety of ZL-1310 compared to Investigator's Choice Therapy in participants with relapsed Small Cell Lung Cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Health Cancer, Detroit, Michigan

   Locations

   155 in total

   Run by

   Zai Lab (Shanghai) Co., Ltd.

   See if you can join NCT07218146 on ClinicalTrials.gov

3. Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer

   This study evaluates a fenretinide phospholipid suspension for the treatment of small cell lung cancer (SCLC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Henry Ford Cancer Institute, Detroit, Michigan

   Locations

   2 in total

   Run by

   SciTech Development, Inc.

   See if you can join NCT06922539 on ClinicalTrials.gov

4. A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

   PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1/PD-1 immunotherapy agent. Up to one additional systemic anti-canc…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Henry Ford Hospital, Detroit, Michigan

   Locations

   30 in total

   Run by

   Puma Biotechnology, Inc.

   See if you can join NCT06095505 on ClinicalTrials.gov

5. A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

   This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Henry Ford Health System, Detroit, Michigan

   Locations

   229 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT06203210 on ClinicalTrials.gov

6. MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

   This study has 2 cohorts: MOZART-ES cohort (for extensive-stage SCLC) and MOZART-LS cohort (for limited-stage SCLC). MOZART-ES cohort: Study treatment will consist of a platinum drug (carboplatin or cisplatin per investigator's choice) plus etoposide plus durvalumab plus monalizumab every 3 weeks f…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Karmanos Cancer Center (Wayne State University), Detroit, Michigan

   Locations

   4 in total

   Run by

   Hirva Mamdani

   See if you can join NCT05903092 on ClinicalTrials.gov